Key result
Metformin is linked to ~24% lower aortic aneurysm risk in type 2 diabetes.
Why the study?
Antidiabetic therapies may contribute to the lower incidence and slower progression of aortic aneurysm observed in patients with T2DM, but comparative large-scale data across different drug classes were limited.
Does exposure to various classes of antidiabetic medications reduce the risk of incident aortic aneurysm in adults with type 2 diabetes mellitus?
Cohort (n=3,432,327)
Yes
Does exposure to various classes of antidiabetic medications reduce the risk of incident aortic aneurysm in adults with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
In a large nationwide cohort of patients with type 2 diabetes, use of metformin, thiazolidinediones, sulfonylureas/meglitinides, α-glucosidase inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists was significantly associated with a lower risk of incident aortic aneurysm, whereas insulin use was associated with an increased risk.
Background Aortic aneurysm (AA) is a life-threatening vascular condition whose development is influenced by multiple cardiovascular risk factors, yet epidemiological studies have paradoxically shown a lower incidence and slower progression of AA in patients with type 2 diabetes mellitus (T2DM). Emerging evidence suggests that antidiabetic therapies, rather than hyperglycemia itself, may contribute to this protective association, although comparative large-scale data across different drug classes remain limited. Purpose This nationwide cohort study used Taiwan’s National Health Insurance database to investigate the associations between various oral antidiabetic medications and the risk of AA in patients with T2DM. Methods This nationwide retrospective cohort study used Taiwan’s National Health Insurance Research Database to identify 3,432,327 adults with type 2 diabetes mellitus between 2006 and 2022, assessing exposure to various antidiabetic medications and incident aortic aneurysm using validated claims-based definitions. Time-to-event analyses were performed with multivariable Cox proportional hazards models incorporating time-varying medication exposure and adjustment for demographic characteristics, comorbidities, and diabetes severity, with subgroup analyses conducted to evaluate the robustness of associations. Results Among 3,432,327 patients with type 2 diabetes mellitus (mean age 60 years; 53% male) followed for a mean of 9.2 years, multivariable time-varying Cox analyses showed that metformin (aHR 0.76, 95% CI 0.73–0.79), thiazolidinediones (aHR 0.72, 95% CI 0.66–0.78), sulfonylureas/meglitinide (aHR 0.84, 95% CI 0.81–0.87), α-glucosidase inhibitors (aHR 0.84, 95% CI 0.79–0.90), SGLT2 inhibitors (aHR 0.87, 95% CI 0.78–0.97), and GLP-1 receptor agonists (aHR 0.66, 95% CI 0.47–0.92) were associated with a lower risk of aortic aneurysm. In contrast, insulin use was associated with a higher risk (aHR 1.31, 95% CI 1.24–1.38), while DPP-4 inhibitors were not significantly associated with risk (HR 0.96, 95% CI 0.91–1.01). These associations were consistent across subgroup analyses stratified by age (<65 vs. ≥65 years), sex, cerebrovascular disease, and chronic kidney disease, without substantial heterogeneity. Conclusions In this nationwide, population-based, retrospective cohort study, we demonstrated that different classes of antidiabetic agents were heterogeneously associated with the risk of AA. After comprehensive multivariable adjustment with time-varying exposure modeling, the risk of AA was significantly lower among users of metformin, sulfonylureas, TZDs, α-glucosidase inhibitors, SGLT2 inhibitors, and GLP-1RA, whereas DPP-4 inhibitors showed a neutral association.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) conducted a cohort in Type 2 diabetes mellitus (n=3,432,327). Antidiabetic drug classes (metformin, thiazolidinediones, sulfonylureas/meglitinide, alpha-glucosidase inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, insulin) vs. Non-use of respective antidiabetic medication class (time-varying exposure) was evaluated on Incident aortic aneurysm (aHR 0.76 (metformin), 95% CI 0.73-0.79). Metformin, TZDs, sulfonylureas, SGLT2is, and GLP-1RAs were associated with lower aortic aneurysm risk in T2DM, whereas insulin increased risk.
Synapse has enriched 10 related papers. Consider them for comparative context: